Most Popular
-
1
Jung's paternity reveal exposes where Korea stands on extramarital babies
-
2
Samsung entangled in legal risks amid calls for drastic reform
-
3
Heavy snow alerts issued in greater Seoul area, Gangwon Province; over 20 cm of snow seen in Seoul
-
4
[Herald Interview] 'Trump will use tariffs as first line of defense for American manufacturing'
![[Herald Interview] 'Trump will use tariffs as first line of defense for American manufacturing'](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/26/20241126050017_0.jpg&u=20241126161719)
-
5
Agency says Jung Woo-sung unsure on awards attendance after lovechild revelations
![[Herald Interview] 'Trump will use tariffs as first line of defense for American manufacturing'](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/26/20241126050017_0.jpg&u=20241126161719)
-
6
[Health and care] Getting cancer young: Why cancer isn’t just an older person’s battle
![[Health and care] Getting cancer young: Why cancer isn’t just an older person’s battle](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/26/20241126050043_0.jpg&u=20241126145342)
-
7
K-pop fandoms wield growing influence over industry decisions
-
8
[Graphic News] International marriages on rise in Korea
![[Graphic News] International marriages on rise in Korea](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/25/20241125050091_0.gif&u=)
-
9
Korea's auto industry braces for Trump’s massive tariffs in Mexico
-
10
Seoul's first snowfall could hit hard, warns weather agency
![[Health and care] Getting cancer young: Why cancer isn’t just an older person’s battle](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/26/20241126050043_0.jpg&u=20241126145342)
![[Graphic News] International marriages on rise in Korea](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/25/20241125050091_0.gif&u=)
Samsung Biologics, AstraZeneca shutting down their joint venture Archigen Biotech
By YonhapPublished : May 24, 2022 - 10:25
Samsung Biologics Co., the biotech arm of South Korea's Samsung Group, is shutting down its joint venture with multinational pharmaceutical company AstraZeneca Plc., a company official said Tuesday, due to the suspension of the development of a biosimilar product.
The move came two months after Samsung Biologics' board approved the liquidation of Archigen Biotech Ltd., a 50-50 joint venture set up with AstraZeneca, in 2014.
Archigen Biotech was responsible for developing SAIT101, a biosimilar of Rituximab, which is used for the treatment of lymphoma. A biosimilar is a very similar copy of an already approved reference biologic drug.
But Samsung Biologics and AstraZeneca reportedly decided to halt the project in the second half of 2020 as competitors, such as Celltrion Inc., have begun selling similar products. (Yonhap)
